$ALHC

KONOWIECKI JOSEPH S sold $525K of ALHC

KONOWIECKI JOSEPH S (EVP, Corporate Affairs) sold 25,000 shares of Alignment Healthcare, Inc. (ALHC) at $21.00 ($0.52M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KONOWIECKI JOSEPH S
Published Jun 12, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure adds incremental sentiment information (insider reduced direct holdings) but provides no new operational or financial guidance.

02

Market read

A planned insider sale may cause minor near-term sentiment drift, but it is unlikely to drive a fundamental repricing alone.

03

What to watch

Insider sales can be scheduled regardless of near-term fundamentals; traders should avoid over-weighting this signal without corroborating news (guidance, trial/regulatory updates, financing).

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The filing is an SEC Form 4 insider transaction for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed an EVP corporate affairs insider open-market sale of 25,000 shares for ~$525K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

Form 4 shows a planned 10b5-1 sale by an officer; without accompanying company-specific operational/regulatory updates, the incremental information is limited.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/compensation mechanics rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction; EVP corporate affairs sold shares.

  • KONOWIECKI JOSEPH S

    EVP, Corporate Affairs; officer/director who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Alignment Shares Tumble on Rising Medical Costs

Alignment Healthcare (ALHC) shares fell 16% after executives cited rising medical costs and claims system issues. CEO John Kao noted the company is addressing these challenges. Despite a 47% drop in the past year, the company maintained its revenue guidance. TD Cowen reiterated a Buy rating with a $21 price target. Alignment is expanding its network with Hoag Memorial Hospital.

$ALHCMed

ALHC Stock Slides As Legal And Cost Pressures Mount

Alignment Healthcare Inc. (ALHC) shares fell 3.61% on September 18, 2026, due to investor concerns over Medicare Advantage reimbursement and regulatory pressures. The stock has dropped significantly from $13–$14 to around $8.35, with technical damage and high volatility. Management cited Q3 medical cost headwinds and additional investments, while a whistleblower alleged expense misclassification, leading to legal probes. Insider selling and weak sentiment have further pressured the stock.

$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.